Vijaya Diagnostic Centre Ltd. AI Stock Analysis
Want to see IN:VIJAYA full AI Analyst Report?
Vijaya Diagnostic Centre Ltd. (VIJAYA) AI Stock Analysis
Vijaya Diagnostic Centre Ltd.
(NSE:VIJAYA)
The score is supported by strong financial performance (consistent growth and resilient margins with moderate leverage) and positive technical momentum (price above major moving averages with positive MACD). These positives are materially offset by expensive valuation (very high P/E and low dividend yield), which increases downside risk if execution or growth disappoints.
Vijaya Diagnostic Centre Ltd. (VIJAYA) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 145.23B
- Dividend Yield
- 0.14%
- Average Volume (3M)
- 9,542
- Price to Earnings (P/E)
- 71.2
- Beta (1Y)
- 0.71
- Revenue Growth
- 24.47%
- EPS Growth
- 34.25%
- Country
- India
- Employees
- 2,507
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Diagnostics & Research
Vijaya Diagnostic Centre Ltd. Business Overview & Revenue Model
Company Description
Vijaya Diagnostic Centre Limited delivers a broad spectrum of diagnostic services to patients across India. Its extensive laboratory offerings include clinical biochemistry, haematology (and immune-haematology), clinical pathology, histopathology, cy...
How the Company Makes Money
VIJAYA primarily earns revenue by delivering diagnostic tests and charging fees for those services. Its key revenue streams are: (1) Pathology/testing revenue: income from clinical laboratory tests (e.g., routine biochemistry, hematology, immunology...
Vijaya Diagnostic Centre Ltd. Financial Statement Overview
Summary
Strong and improving revenue growth (accelerating to 11.32% in 2026) with durable profitability (net margin ~21% and EBITDA margin low-to-mid 40s in 2024–2026). Balance sheet is healthy with moderate leverage (debt-to-equity ~0.40–0.45), but absolute debt rose in 2026. Operating cash flow is consistently strong versus net income, though free cash flow conversion is uneven and weakened in 2026, and gross margin showed notable volatility (sharp drop in 2023).
Income Statement
86Very PositiveBalance Sheet
78PositiveCash Flow
74Positive| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.11B | 8.14B | 6.81B | 5.48B | 4.59B | 4.62B |
| Gross Profit | 6.80B | 7.20B | 5.96B | 4.82B | 4.00B | 3.91B |
| EBITDA | 4.00B | 3.58B | 2.88B | 2.38B | 1.95B | 2.15B |
| Net Income | 2.04B | 1.73B | 1.43B | 1.19B | 846.32M | 1.10B |
Balance Sheet | ||||||
| Total Assets | 17.33B | 15.07B | 12.74B | 9.83B | 8.53B | 7.13B |
| Cash, Cash Equivalents and Short-Term Investments | 3.49B | 2.89B | 2.33B | 1.85B | 2.55B | 2.25B |
| Total Debt | 5.09B | 4.23B | 3.20B | 2.59B | 2.48B | 1.83B |
| Total Liabilities | 6.76B | 5.50B | 4.74B | 3.23B | 3.07B | 2.44B |
| Stockholders Equity | 10.57B | 9.57B | 7.96B | 6.57B | 5.45B | 4.68B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 878.75M | 1.29B | 953.37M | 397.69M | 356.50M |
| Operating Cash Flow | 0 | 2.71B | 2.24B | 1.83B | 1.65B | 1.58B |
| Investing Cash Flow | 0 | -1.74B | -1.82B | -1.42B | -1.10B | -1.23B |
| Financing Cash Flow | 0 | -694.88M | -520.48M | -445.50M | -419.12M | -305.72M |
Vijaya Diagnostic Centre Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:VIJAYA, the sentiment is Negative. The current price of 1410.55 is below the 20-day moving average (MA) of 1419.99, below the 50-day MA of 1456.16, and above the 200-day MA of 1251.26, indicating a neutral trend. The MACD of -3.32 indicates Negative momentum. The RSI at 44.99 is Neutral, neither overbought nor oversold. The STOCH value of 25.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:VIJAYA.
Vijaya Diagnostic Centre Ltd. Peers Comparison
Overall Rating
IN:LALPATHLAB82Outperform- IN:VIJAYA70.75Outperform
IN:KRSNAA70Outperform
IN:SURAKSHA66Neutral
IN:THYROCARE65Neutral
IN:METROPOLIS59Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| IN:LALPATHLAB | 82Outperform | INR 337.21B | 57.14 | ― | 0.88% | 16.71% | 9.15% |
| IN:VIJAYA | 71Outperform | INR 145.67B | 71.25 | ― | 0.14% | 24.47% | 34.25% |
| IN:KRSNAA | 70Outperform | INR 16.79B | 17.48 | ― | 0.38% | 15.90% | 15.67% |
| IN:SURAKSHA | 66Neutral | INR 17.74B | 42.55 | ― | 0.29% | 25.33% | 30.99% |
| IN:THYROCARE | 65Neutral | INR 77.64B | 55.05 | ― | 1.87% | 21.99% | 12.77% |
| IN:METROPOLIS | 59Neutral | INR 117.26B | 52.14 | ― | 0.35% | 19.84% | 41.41% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:VIJAYA | Vijaya Diagnostic Centre Ltd. | 1410.55 | 373.54 | 36.02% | |
| IN:KRSNAA | Krsnaa Diagnostics Limited | 528.55 | -296.05 | -35.90% | |
| IN:LALPATHLAB | Dr. Lal PathLabs Limited | 1991.75 | 428.69 | 27.43% | |
| IN:METROPOLIS | Metropolis Healthcare Ltd. | 563.60 | 69.67 | 14.11% | |
| IN:SURAKSHA | Suraksha Diagnostic Ltd. | 341.70 | 40.77 | 13.55% | |
| IN:THYROCARE | Thyrocare Technologies Ltd | 498.40 | -14.65 | -2.86% |
Vijaya Diagnostic Centre Ltd. Corporate Events
Vijaya Diagnostic Centre CTO Resigns, Technology Leadership Transition Ahead
Vijaya Diagnostic Centre has announced that its Chief Technology Officer, Sai Siva Prasad, has resigned from the company for personal reasons, with his last working day set for August 8, 2026. The board has formally recorded its appreciation for his...
Vijaya Diagnostic Centre Plans Singapore Non-Deal Roadshow with Institutional Investors
Vijaya Diagnostic Centre Limited has announced that its officials will hold in-person one-on-one meetings with institutional investors and analysts in Singapore on June 15 and 16, 2026, as part of a non-deal roadshow organized by Emkay Global Financi...
Vijaya Diagnostic Centre Announces Completion of Tenure for Two Independent Directors
Vijaya Diagnostic Centre Ltd. has announced that non-executive independent directors Shekhar Prasad Singh and Satyanaryana Murthy Chavali have ceased to be directors of the company following the completion of their respective tenures as of the close...
Vijaya Diagnostic Announces Completion of Tenure for Two Independent Directors
Vijaya Diagnostic Centre has announced that non-executive independent directors Shekhar Prasad Singh and Satyanarayana Murthy Chavali have completed their tenures and ceased to be directors as of the close of business on May 25, 2026. The board has r...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 17, 2026